Partillion Bioscience Corporation Announces Seed Financing, Expanded Board, And New Partnership With Alloy Therapeutics
Partillion Bioscience Corporation Announces Seed Financing, Expanded Board, And New Partnership With Alloy Therapeutics
09/26/23, 1:45 PM
Location
Industry
biotechnology
Round Type
seed
Investors
Alloy Therapeutics, Paladin Capital, Vertical Venture Partners, Nd Capital, General Inception, Initiate Studios, Alloy Therapeutics, Inc.
Partillion Bioscience Corporation ("Partillion"), a life science tools company, today announced the closing of a $5 million seed financing round, expansion of its board of directors, and a multiyear agreement with Alloy Therapeutics, Inc. as a Preferred Partner providing antibody discovery services using Partillion's Nanovial technology. Nanovials solve numerous industry challenges as the first microscale test tubes engineered for the isolation and analysis of individual cells that are compatible with standard laboratory equipment. The investment follows the earlier incubation support from venture studio partners Initiate Studios and General Inception
Company Info
Location
2360 glendon ave.
los angeles, california, united states
Additional Info
Partillion Bioscience is an early stage life science company aiming to democratize advanced single-cell assays with its award-winning nanovial platform. Our novel platform allows the rapid compartmentalization and analysis of millions of single cells to probe biological function such as secreted proteins. The validated technology underpinning Partillion’s products has been featured in notable journals such as Science Advances, Advanced Functional Materials, and Lab on Chip and received industry accolades, winning the 2020 SLAS Innovation Award.